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ABSTRACT
Prion protein (PrPC) is a cell surface glycoprotein whose misfolding is responsible 
for prion diseases. Although its physiological role is not completely defined, several 
lines of evidence propose that PrPC is involved in self-renewal, pluripotency gene 
expression, proliferation and differentiation of neural stem cells. Moreover, PrPC 
regulates different biological functions in human tumors, including glioblastoma 
(GBM). We analyzed the role of PrPC in GBM cell pathogenicity focusing on tumor-
initiating cells (TICs, or cancer stem cells, CSCs), the subpopulation responsible 
for development, progression and recurrence of most malignancies. Analyzing four 
GBM CSC-enriched cultures, we show that PrPC expression is directly correlated 
with the proliferation rate of the cells. To better define its role in CSC biology, 
we knocked-down PrPC expression in two of these GBM-derived CSC cultures by 
specific lentiviral-delivered shRNAs. We provide evidence that CSC proliferation 
rate, spherogenesis and in vivo tumorigenicity are significantly inhibited in PrPC 
down-regulated cells. Moreover, PrPC down-regulation caused loss of expression 
of the stemness and self-renewal markers (NANOG, Sox2) and the activation of 
differentiation pathways (i.e. increased GFAP expression). Our results suggest that 
PrPC controls the stemness properties of human GBM CSCs and that its down-regulation 
induces the acquisition of a more differentiated and less oncogenic phenotype.
INTRODUCTION
Cellular prion protein (PrPC) is a cell surface 
glycoprotein, highly conserved in all mammalian species. 
PrPC is considered at the basis of the pathogenesis of prion 
diseases, in which the fundamental event is its misfolding 
into a protease-insensitive, amyloidogenic isoform (PrPSc) 
[1]. Misfolded PrPC accumulates in intra- and extracellular 
deposits as insoluble protein aggregates [2, 3] responsible 
of neurotoxicity and astrogliosis [4–8]. The conversion 
of PrPC into PrPSc consists in a radical modification of 
its three-dimensional structure and, consequently, of 
its biochemical and biological properties [9–11]. The 
“protein only” hypothesis [1] postulates that PrPSc, in 
an autocatalytic reaction, duplicates itself inducing its 
abnormal spatial structure on newly synthesized PrPC 
molecules [12, 13]. PrPC is highly expressed within the 
central nervous system (CNS), although its content varies 
among distinct brain regions, among different cell types 
and/or neurons with distinct neurochemical phenotypes 
[1]. Various cellular components of the immune system, 
in bone marrow, blood, and peripheral tissues, also 
express substantial amounts of PrPC [14]. However, even 
though several studies have been performed to define its 
physiological function, there are still no unequivocal data 
able to define a precise cellular function of PrPC.
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PRNP (the PrPC gene)-knockout experiments did not 
evidence particular alterations in mice, indicating that PrPC 
is not essential for normal development or that PrPC loss 
of function can be compensated by other molecules [15]. 
In search for a physiological function for this protein, PrPC 
was proposed to protect neurons against cell death and 
oxidative stress [16], to control copper metabolism [17], 
to regulate cell cycle [18], synaptic transmission [19], and 
cell adhesion [20], and to activate the immune system [21]. 
Interestingly, more recent studies suggested that PrPC plays 
a role in pluripotency and differentiation of embryonic 
stem cells [22], cell proliferation and differentiation [23–
28], and muscle cell regeneration [29], through the direct 
activation of the Src-family kinase Fyn, at least as far as 
the CNS effects [30]. Starting from these observations 
PrPC has been intriguingly involved in the development 
of human tumors [22, 31], including glioblastoma 
[32, 33], and gastric [34], breast [35], prostate [36], and 
colorectal [37] carcinomas. For example, PrPC expression 
was correlated with increased cell proliferation in gastric 
cancer cell lines [18, 38], and PrPC overexpression was 
shown to provide cancer cells with resistance to cytotoxic 
agents [36], and higher invasive properties [39].
Cancer stem cells (CSCs, also called tumor-initiating 
cells, TICs, due to their in vivo tumorigenic activity) 
derive their denomination from several phenotypical and 
functional characteristics shared with normal stem cells 
[40] and were identified over a decade ago in glioblastoma 
(GBM), the most common and aggressive CNS tumor 
[41]. GBM CSCs are resistant to conventional chemo-
radiotherapy due to high activity of DNA repairing 
enzyme and drug efflux pumps, and their persistence 
after cytotoxic therapy is believed to determine tumor 
recurrence [42, 43]. In virtue of these proprieties, GBM 
CSCs represent the focus for novel targeted therapies 
[44, 45]; moreover, the identification of specific signaling 
pathways responsible for the retention of stemness, might 
have a significant translational relevance, contributing to 
the eradication of this cell subpopulation.
CSC-enriched cultures can be obtained from post-
surgical GBM specimens using the protocols adopted 
to isolate neural stem cells [46]. They are able to grow 
indefinitely in serum-free medium, supplemented with 
growth factors (EGF and bFGF) [47], as non-adherent 
cultures that generate three-dimensional spheroids, an in 
vitro index of self-renewal [48]; moreover, CSC cultures 
can differentiate into different brain cell lineages and 
are tumorigenic when orthotopically xenografted in 
immunodeficient mice [49].
Here we report the role of PrPC in regulating CSCs 
phenotype and functioning. In particular, we analyzed 
the effects of the down-regulation of PrPC expression in 
CSCs isolated from human GBMs. We report that PrPC 
expression restrains GBM CSCs from differentiation, 
conferring them distinctive stem cell-like features, such 
as self-renewal ability and in vivo tumorigenicity.
RESULTS
PrPC expression level correlates with the 
proliferation rate of human GBM CSCs
To establish a functional role for PrPC in human 
GBM CSCs, we analyzed the relationship between 
native PrPC expression levels and proliferation rate in 
four different CSC-enriched cultures, named GBM1-4, 
isolated from human GBMs. PrPC expression was 
assessed by immunoblot (Figures 1A and 1B). We 
observed significant differences in PrPC expression 
among CSCs from the different tumors. Densitometric 
analysis of immunoreactive bands demonstrated that 
GBM1 CSCs express the highest level of PrPC respect 
to the other cultures, being four times the expression 
observed in GBM2, two times that of GBM3, about 1 
time more than GBM4 (Figure 1B). By MTT reduction 
assay, we analyzed, up to 72 hrs., the CSC proliferation 
rate. As shown in Figure 1C, GBM1 CSCs displayed 
the highest proliferation rate, followed by GBM4, while 
GBM3 and GBM2 CSCs have slower duplication time. 
Linear regression analysis, correlating PrPC expression and 
cell proliferation at 72 hrs., revealed a direct correlation 
between these parameters (Figure 1D), with a highly 
significant statistical relationship (R2: 0.9).
Stable silencing of PrPC mRNA and protein in 
human GBM stem cell-enriched cultures by 
shRNA
To delve deeper in to the role of PrPC expression 
in GBM cell proliferation, and analyze the role of this 
protein in the defining properties of CSCs, we evaluated 
the effects of PrPC downregulation by gene silencing 
using specific shRNA. We analyzed CSCs from GBM1 
and GBM2, representing the cultures with the highest and 
the lowest levels of PrPC. GBM1 and GBM2 CSCs were 
transfected with PrP shRNA, using a pool of 3 target-
specific lentiviral plasmids, each encoding 19-25 nt (plus 
hairpin) designed to knock-down gene expression. To 
generate control cultures, GBM1 and GBM2 cells were 
also transfected with a plasmid encoding a scrambled 
(Scr) shRNA sequence, which does not target any known 
cellular mRNA. Transfected cells were selected with 
puromycin and the stable PrPC knock-down cultures were 
named GBM1-PrP-KO and GBM2-PrP-KO, while cells 
transfected with the scrambled shRNA sequence were 
named GBM1-Scr and GBM2-Scr. The efficiency of 
PrPC knock-down was verified by quantitative Real Time 
PCR (qRT-PCR) analysis (Figure 2A) and immunoblot 
(Figures 2B and 2C), showing a significant reduction 
of PrPC expression in both GBM-PrP-KO cell cultures. 
In particular, densitometric analysis of immunoreactive 
bands showed a decrease of PrPC protein expression of 
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about 80% in GBM1-PrP-KO and 60% for GBM2-PrP-
KO cells vs. respective controls (GBM-Scr) (Figure 2C).
PrPC knockdown reduces proliferation of GBM 
CSCs
Proliferation of GBM PrP-KO and Scr cells was 
tested by MTT reduction assay, that measures mitochondrial 
activity as an index of cell viability being proportional to 
cell number, by counting cell number, using an automated 
cell counter, and by BrdU incorporation assay, which 
evaluates DNA synthesis.
For MTT assays, GBM CSCs were plated at the 
concentration of 2.5x104/well, and cell number was 
evaluated after 24, 48 and 72 hours. GBM1- and GBM2-
PrP-KO cells showed a significantly reduced proliferation 
rate (Figures 3A and 3B), as compared to the respective 
GBM-Scr control cells. The effect was more evident in 
GBM1-PrP-KO in which PrPC mRNA silencing was 
more pronounced, but in both cell cultures the differences 
become bigger with the increasing of the time.
It is important underline that, in MTT experiments, 
we did not observe significant difference in growth curve 
between non-transfected (wild type) GBM CSCs and 
GBM-Scr (control transfected cells, data not shown), 
confirming that the expression of the Scr sequence does 
not influence the proliferation rate of GBM CSCs. These 
experiments were confirmed by automated cell counting 
(Figure 3C) evaluated up to 3 days after cell plating. 
GBM1 Scr cells showed the highest proliferation levels 
and the two PrP-KO cultures the slowest duplication 
activity. Moreover, the quantification of cell death by 
Trypan Blue exclusion test, did not reveal significant 
difference between GBM-Scr and GBM-PrP-KO cell 
cultures (about 5% in all the cultures evaluated, data not 
shown) suggesting that the reduction of PrP expression is 
not cause of toxicity but effectively interferes with cell 
proliferation. These data were confirmed in experiments 
Figure 1: A. Representative immunoblot analysis of PrPC protein level in 4 different wt GBM CSC cultures. PrPC content was determined 
by 3F4 immunoreactivity. Immunoblotting for β-actin was used to normalize the results for the total content of proteins. B. Quantification 
of PrPC protein level, reported as densitometric analysis of blots as in panel A, derived from three independent experiments and expressed 
as percentage of wt GBM2, 3, 4 immunoreactive bands vs. wt GBM1. **p < 0.01 vs. wt GBM2, 3, 4 CSCs, °°p < 0.01 vs. wt GBM 1, 
2, 3 wt CSCs; ++p < 0.01 vs. wt GBM 1, 2, 4 CSCs. C. Growth curve of wt GBM 1-4 CSC cultures. Cell proliferation was evaluated by 
MTT reduction test. Values, taken as percentage of the values at time 0, are the average of two independent experiments, performed in 
quadruplicate. **p < 0.01 vs. GBM2,3,4, wt cells and °°p < 0.01 vs. GBM1,2,3 wt cells D. Linear regression analysis of the relationship 
between PrPC expression and the proliferation rate of GBM1-4 CSC cultures.
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in which BrdU incorporation, during DNA synthesis, 
was measured by specific ELISA (Figure 3D). GBM 
cells were plated at the concentration of 1x104/well, and 
BrdU incorporation evaluated after 24 and 48 hrs. DNA 
synthesis in GBM1-PrP-KO and GBM2-PrP-KO cells was 
significantly reduced as compared to the respective GBM 
Scr cells (about -30% after 24 hours in both GBM-PrP-KO 
cultures, about -50% in GBM1-PrP-KO and about -40% in 
GBM2-PrP-KO cells, after 48 hours).
Finally, the role of PrPC in GBM cell proliferation 
was further confirmed in wild type GBM CSCs, analyzing 
the effect of two anti-PrP antibodies in the MTT assay. In 
fact, it was reported that the anti-PrP antibodies causes 
the inhibition of PrPC dimerization and the consequent 
intracellular signaling, inducing neurotoxic effects in 
neural progenitors [50, 51] and reduced tumorigenicity 
of colon CSCs [37]. We tested the effect of two specific 
anti-PrP antibodies, the clones 3F4 (epitope corresponding 
to amino acids 109–112 in the human PrP) and SAF 32 
(epitope corresponding to amino acids 63-94 in the human 
PrP) on wild type GBM1 and GBM2 CSC proliferation. 
The treatment for 48 hrs. with different antibody 
concentrations confirmed that the interference with PrPC 
signaling causes a statistically significant reduction of 
the proliferation rate (-28 and -22%, p<0.01, with 1mg/
ml of both 3F4 and SAF32, respectively in GBM1 cells, 
Figure 2: A. Prion protein mRNA expression in GBM1 (left) and GBM2 (right), evaluated by quantitative RT-PCR. PRNP expression 
values in GBM PrP-KO cells (grey bars) were normalized vs. respective GBM-Scr cells (white bars). Results are expressed as means ± SEM. 
**p < 0.01 vs. respective GBM-Scr cells. B. Immunoblotting analysis of PrPC protein level in GBM1 (left) and GBM2 (right) cells. PrPC 
content was determined by 3F4 immunoreactivity by Western blot. Immunoblotting for β-actin was used to normalize the results for 
the total content of proteins. C. Quantification of PrPC protein level, reported as densitometric analysis of the blots derived from three 
independent silencing experiments and as expressed percentage of GBM PrP-KO (grey bars) 3F4-immunoreactive bands vs. GBM-Scr 
(white bars). **p < 0.01 vs. respective GBM-Scr cells.
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and -19%, p<0.01 and -13%, p<0.05 with 2mg/ml of 3F4 
and SAF32, respectively in GBM2 cells, data not shown). 
These findings confirm that PrPC plays an important role 
in the regulation of GBM CSC proliferation, and that 
the effects observed in the PrPC-KO cells are effectively 
dependent on the reduction of the PrPC signaling and not 
due to shRNA off-target effects.
PrPC controls clonogenicity and self-renewal of 
GBM CSCs
To verify whether, besides proliferation, PrPC down-
regulation also affects distinctive features of GBM CSCs, 
we compared the clonogenic activity of GBM-Scr and 
GBM-KO cultures, as in vitro index of stemness. GBM-
Scr and PrP-KO cells were seeded onto matrigel, by 
limiting dilution in order to obtain a concentration lower 
than 1 cell/well. After 15 days in culture, individual wells 
were visually inspected under a phase contrast microscope 
and the developed clones counted. A dramatic reduction in 
clone formation occurred in both GBM-PrP-KO cultures 
as compared to the respective GBM-Scr cells (Figure 4A). 
Again, the reduction in clonogenic activity was much 
more evident in PrP-silenced CSCs derived from GBM1 
than in cells isolated from GBM2, providing a further 
correlation between the levels of PrPC down-regulation 
and CSC functional properties.
The loss of clonogenicity in GBM-PrP-KO cells 
suggested that other key features of CSC subpopulation 
might be affected by the down-regulation of PrPC 
expression. Thus, we analyzed the differential ability of 
PrP-KO and Scr cells to grow as gliomaspheres, considered 
an in vitro index of self-renewal activity [52]. GBM-Scr 
and PrP-KO cells were seeded at the concentration of 1000 
Figure 3: A-B. Proliferation curves of GBM1-PrP-KO and GBM1-Scr (A) and GBM2-PrP-KO and GBM2-Scr (B) cells assessed by 
MTT assay after 24, 48 and 72 hours. Each point represents the average of three experiments performed in quadruplicate. **p < 0.01 vs. 
respective GBM-PrP-KO cells. C. Proliferation curves of GBM1-PrP-KO, GBM1-Scr, GBM2-PrP-KO and GBM2-Scr cells assessed by 
cell count after 24, 48 and 72 hours of proliferation. Each point represents the average of three experiments performed in quadruplicate. 
**p < 0.01 vs. GBM1-PrP-KO. °°p < 0.01 vs. GBM2-PrP-KO. D. DNA synthesis rate of GBM1-PrP-KO and GBM2-PrP-KO cells in 
comparison with respective GBM-Scr control cells, determined by BrdU incorporation assay after 24 and 48 hours. Data are expressed as 
a percentage of respective GBM-Scr cells, and each point represents the average of three experiments, performed in quadruplicate. **p < 
0.01 vs. respective GBM-Scr cells.
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Figure 4: A. Quantification of clonogenic activity of GBM1- and GBM2- Scr and PrP-KO cells, expressed as percentage of the number of 
plated cells, assumed as 100%. Each point represents the average of three experiments performed in quadruplicate. **p < 0.01 vs. GBM-Scr 
cells. B. Representative micrographs of the sphere formed by GBM-Scr and GBM-PrP-KO cells after 7 days of growth (using 5x/012 Leica 
Objective). These data underline that PrP-KO cells derived from both GBM1 and GBM2 form rare small spheroids. C. Limiting dilution 
analysis comparing stem cell of sphere formation between by GBM-Scr and GBM-PrP-KO cells after 15 days of growth in complete 
medium in 96 well ultra-low adherent plates. Plating density ranges from 100 to 0.01 cells/well. **p<0.01 vs. GBM1-PRP-KO cells, 
°°p<0.01 vs. GBM2-PRP-KO cells.
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cells/well, without matrigel coating. After 15 days, sphere 
formation was analyzed by light microscopy. Contrarily to 
control GBM-Scr, GBM-PrP-KO cells are unable to form 
spheroids, resulting in the formation of only few small cell 
aggregates (Figure 4B). Moreover, we performed sphere 
limiting dilution experiments. As reported in Figure 4C, a 
dramatic reduction in the percentage of sphere formation 
occurred in both GBM-PrP-KO cultures compared to 
the respective GBM-Scr cells. Counting the number of 
wells in which spheres developed, we observed that the 
difference in sphere formation efficiency was maximal 
in the wells containing only one cell, being detected a 
sphere in less than 20% of the wells containing PrPC-KO 
CSC, vs. about 50% of the GBM-Scr. The estimation of 
sphere-forming probability by linear regression analysis 
as described by [53], showed that the down-regulation 
of PrPC reduced the spherogenic activity by more than 
three times in GBM1 and by two-fold in GBM2. These 
data clearly support the possibility that the lack of 
PrPC expression in GBM CSCs affects not only in vitro 
proliferation rate but also relevant stemness features, such 
as self-renewal.
PrPC expression controls the stem cell-like 
phenotype in human GBM CSCs
To confirm the role of PrPC as a stemness regulator 
of GBM CSCs, we investigated phenotype alterations 
induced by PrPC down-regulation, focusing on mRNA 
and protein levels of Sox2 and NANOG, two transcription 
factors essential for maintaining self-renewal and 
pluripotency, not only in human embryonic [54] and 
neural stem cells [55] but also in human GBM CSCs [56].
Sox2 mRNA content, analyzed by qRT-PCR, 
was significantly reduced in both GBM-PrP-KO cells 
(about -70% in GBM1- and GBM2-derived CSCs) (Figure 
5A). These results were confirmed at protein level by 
Western blot (Figures 5B and 5C), in which GBM1- and 
GBM2-PrP-KO displayed a significant reduction of Sox2 
expression (approximately -80% of the respective GBM-
Scr cells).
Similar results were obtained as far as the expression 
of NANOG, a transcription factor expressed in CSCs in 
which regulates cell death and proliferation [57, 58]. By 
qRT-PCR and Western blot experiments, we demonstrated 
that NANOG mRNA and protein contents (Figure 6A, 6B 
and 6C) are significantly reduced in GBM CSC cultures in 
which PrPC is down-regulated.
In GBM-PrP-KO CSCs the loss of stemness 
regulators was associated with increased levels of the 
astrocytic differentiation marker glial fibrillary acidic 
protein (GFAP). We show that, while GBM-Scr cells, 
grown in serum-free, EGF/bFGF-containing medium, 
do not show signs of spontaneous differentiation 
(i.e. no GFAP expression evaluated by both Western 
blot and immunocytofluorescence), GBM-PrP-KO 
cultures (from both GBM1 and GBM2), grown in the 
same conditions, display a spontaneous basal expression 
of GFAP in several cells (Figures 7 and 8). GBM CSCs 
can be induced to differentiate by shifting the culture 
conditions from a growth factor-containing medium to 
a medium enriched with 10% FBS [46, 49]. Similarly to 
native GBM1 and GBM2 CSCs (data not shown), GBM1- 
and GBM2-Scr, after 2 weeks of growth in differentiating 
culture conditions (10% FBS) underwent to morphological 
changes and increased GFAP expression in almost all the 
cells (Figure 7 and 8). However, this effect was greatly 
accelerated in GBM1-PrP-KO and GBM2-PrP-KO cells 
in which a significant increase in GFAP expression was 
evident after only 6 days from the beginning of the 
differentiation process (evaluated by both Western blot 
and immunocytofluorescence, Figures 7 and 8).
These data, altogether with the reduced expression 
of transcription factors related to pluripotency and self-
renewal, clearly demonstrated that PrPC expression 
controls the subtle equilibrium between stemness and 
differentiation of human GBM CSCs.
PrPC expression influences tube formation in 
human GBM CSCs
Normal neural stem cells are able to differentiate 
into functional endothelial cells. The connection between 
neural stem cells and the endothelial compartment seems 
to be critical in glioblastoma, where CSCs closely interact 
with the vascular niche and promote angiogenesis through 
the release of vascular endothelial growth factor and 
CXCL12 in an autocrine/paracrine manner [59–62]
Starting from this evidence, we evaluated whether 
PrPC expression influences GBM-CSCs ability to 
transdifferentiate into endothelial-like cells performing 
an in vitro tube formation assay. In order to induce tube 
formation, CSCs were seeded on matrigel-coated “μ–Slide 
Angiogenesis” and incubated at 37°C for 24h, in medium 
formulated to sustain endothelial cell growth in vitro. As 
shown in Figure 9A, in these experimental conditions 
both GBM-PrP-KO cultures were able to form more 
vessel-like structures than GBM-PrP Scr. This process 
was quantified by mean loop perimeter (Figure 9B) and 
mean of branching points (Figure 9C), confirming that 
PrPC down-regulation favors GBM-CSC differentiation 
process.
PrP knockdown reduces tumorigenic potential of 
GBM CSCs
According to the hierarchical tumorigenesis theory, 
only the small CSC subpopulation, among all the cells in 
the tumor mass, is endowed with tumorigenic potential 
(thus they are called tumor-initiating cells, TIC). To 
demonstrate that PrPC is involved in this fundamental 
CSC property, we compared the ability of GBM-Scr and 
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GBM-PrP-KO cells to develop tumors in an orthotopic 
mouse model. Cells (10,000/mice) were intracranially 
xenografted in NOD/SCID mice [46, 49]. Tumors were 
allowed to develop for about 3 months and animal 
receiving control GBM-Scr cells were sacrificed when 
showing signs of suffering due to the excessive growth 
of the tumor. Mice injected with GBM-PrP-KO cells, that 
did not display pathological sings during the observation 
period, were sacrificed along the last control mice. By 
immunohistochemical analysis we observed that all the 
mice studied developed tumors, but brains xenografted 
with both GBM1- and GBM2-Scr cells showed the 
Figure 5: A. Expression of Sox2 mRNA in GBM1- and GBM2-PrP-KO cells, evaluated by quantitative RT-PCR. Sox2 expression values 
were normalized to respective GBM-Scr cells (white bars). Results are expressed as means ± SEM . **p<0.01 vs. respective GBM-Scr cells. 
B. Representative immunoblots of Sox2 protein expression level in GBM-Scr and GBM PrP-KO cells. Immunoblot analysis of β-actin 
levels was performed to normalize the data for the total protein input of cell lysates. C. Densitometric analysis of Sox2 expression from 
three independent Western blot experiments and expressed as percentage of GBM-Scr cells ± SEM. **p<0.01 vs. respective GBM-Scr cells.
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presence of large tumor masses, with a diffuse tumor 
invasion of the brain parenchyma (Figure 10A, 10B), 
while the injection of GBM1- and GBM2-PrP-KO cells, 
analyzed at the same time after the injection, caused the 
formation of very small tumors. Interestingly, tumors 
originated from GBM1-PrP-KO showed a significant 
lower dimension than those formed by GBM2-PrP-KO, 
further confirming a relationship between the levels of 
PrPC expression and the loss of CSC features. Moreover, 
cells composing these minimal tumors showed expression 
of PrPC, when labeled with 3F4 anti-human PrPC antibody 
(Figure 10C). This observation suggests that these tumors 
originate from small cell subpopulations, which, once 
injected in vivo (or possibly already present in very small 
Figure 6: A. Expression of NANOG mRNA in GBM1 and GBM2-Scr and PrP-KO cells, evaluated by quantitative RT-PCR. NANOG 
expression values were normalized to respective GBM-Scr cells (white bars). Results are expressed as means ± SEM . **p < 0.01 vs. 
respective GBM-Scr cells. B. Representative immunoblots of NANOG protein expression level in GBM-Scr and GBM PrP-KO cells. 
Immunoblot analysis of β-actin levels was performed to normalize the data for the total protein input of cell lysates. C. Densitometric 
analysis of NANOG expression from three independent Western blot experiments and expressed as percentage of GBM-Scr cells ± 
SEM.**p<0.01 vs. respective GBM-Scr cells.
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Figure 7: A. Representative immunoblots of GFAP expression in GBM-Scr and GBM-PrP-KO cells. Cells were analyzed after growing 
in stem cell permissive medium (time 0), or after cell differentiation, induced by incubation for 6 or 15 days in medium deprived of 
growth factors and additioned with 10% FBS. Immunoblot analysis of β-actin was performed to verify the total protein input in the cell 
lysates. B. GFAP expression is reported as densitometric analysis of the gels derived from three independent experiments and expressed as 
percentage of the highest intensity value of GFAP/β-actin ratio. Cells were analyzed after growing the cells in stem cell permissive medium 
(day 0), or after inducing cell differentiation by incubation for 6 or 15 days in medium deprived of growth factors and additioned with 10% 
FBS. **p<0.01 vs. respective GBM-Scr cells.
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Figure 8: Immunofluorescence analysis of GFAP expression (green) at time 0, after 6 and 15 days of differentiation in 
medium containing 10% FBS. Nuclei were counterstained with DAPI (blue) and cells morphology was evidenced by staining with 
Dil, a lipophilic red-fluorescent dye. Magnification 40X.
Figure 9: Effect of PrPC down-regulation on the ability of GBM CSCs to form endothelial tubes. A. Representative 
micrographs of tube formation in GBM-Scr and GBM-PrP-KO cells after 24h of growth in endothelial differentiation medium. B. Mean 
loops tube perimeter and C. mean branching points formation, induced in GBM cells by endothelial transdifferentiation. Perimeters 
are expressed in pixel. Data are expressed as percentage of respective GBM-Scr cell value. Each point represents the average of three 
independent experiments. **p<0.01 vs. GBM1-Scr cells, °°p<0.01 vs. GBM2-Scr cells
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percentage in vitro) lose the mRNA silencer, and the re-
expression of PrPC granted the reacquisition of the in vivo 
tumorigenic activity.
All together these results clearly confirm that PrPC 
is an important requirement for CSC to develop GBM 
in vivo.
DISCUSSION
In the past years, one of the main issue in prion 
research has been the quest for a physiological role for 
PrPC [63]. In fact, although highly concentrated within the 
CNS, this membrane-bound extracellular glycoprotein, is 
ubiquitous in humans and extremely conserved throughout 
the evolution. In this context, several studies proposed that 
PrPC is involved in the regulation of stem cell self-renewal, 
proliferation and differentiation [64, 65]. Moreover, more 
recently it was suggested that PrPC might also promote 
human tumor development and diffusion, and the induction 
of drug resistance [22, 36]. PrPC overexpression was 
observed in gastric cancer lesions as compared to non-tumor 
tissues representing a predictive marker of poor prognosis 
[66], while PrPC down-regulation reduced tumor cell 
proliferation [67] or caused cell death via the activation of 
the autophagic pathway [68]. However, most of these studies 
have been performed in continuous cell lines evaluating 
the effects of PrPC on the biological behavior of the cells. 
According to the current theory of tumorigenesis, CSCs are 
pivotal mediators of tumor development, representing the 
real pharmacological target to obtain efficacious treatments 
[43, 69]. Conversely, it was shown that prolonged in vitro 
growth in FBS-containing medium (as occurs in established 
cell lines) causes the loss of the main malignant features 
observed in CSCs (in vivo tumorigenesis, self-renewal, etc.) 
altering the pharmacological sensitivity of these cultures 
[70]. As far as PrPC is concerned, only few studies directly 
analyzed its role in the regulation of CSC biology. It was 
shown that PrPC silencing reduced the metastatic potential 
of CSCs sorted from human colorectal cancers as CD44+, 
a stem-like membrane receptor involved in cell adhesion, 
motility, and metastasis. This effect was mimicked by the 
administration of anti-PrP antibodies [37]. Moreover, the 
direct interaction between PrPC and CD44 is determinant for 
the multi-drug resistant phenotype in breast cancer cells [67].
In the current study, we examined the role of 
PrPC in GBM stem cell functioning. Starting from 
the observation of a direct correlation between PrPC 
expression levels and proliferation rate of four CSC-
enriched cultures derived from individual human GBMs, 
we deeper analyzed this correlation taking advantage of 
two GBM CSC cultures in which PrPC expression was 
significantly reduced by the stable transfection of specific 
shRNA. Wild type (native) or control (transfected with 
scrambled shRNA sequences) GBM CSCs retain similar 
levels of in vitro self-renewal activity, expression of 
neural stem cell markers, and both are highly tumorigenic 
when orthotopically grafted in immunocompromised 
mice. Moreover, when grown in FBS-containing medium, 
wild type and control GBM CSCs differentiate into 
cells resembling the population composing the bulk of 
Figure 10: Role of PrPC in the in vivo tumorigenicity of human GBM CSCs. A. Representative images of tumors developed 
in NOD/SCID mice orthotopically grafted with GBM1- or GBM2-Scr, and GBM1- or GBM2-PrP-KO cells. After sacrifice of the animals, 
brains were fixed and stained with hematoxylin and eosin (H&E), showing that GBM1- and GBM2-Scr cells developed larger and more 
invasive tumors, as compared to the respective GBM PrP-KO cells. B. Quantification of GBM 1 and 2 brain invasion area, evaluated as 
percentage of total brain area. **p<0.01 vs. respective GBM-Scr cells. C. Representative immunofluorescence analysis of PrP expression 
(antibody 3F4, green) in tumors originated from GBM1-PrP-KO. Nuclei were counterstained with DAPI (blue).
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tumors mass [46, 49, 71], expressing neuronal and glial 
markers, but losing the tumorigenic activity in mouse 
models, according to the hierarchical model of tumor 
development. In this study, we show that the reduction of 
the expression of PrPC in GBM CSCs: (a) decreases cell 
proliferation rate; (b) dramatically reduces self-renewal 
(as evaluated by spherogenesis activity) and clonogenic 
activities; (c) promotes spontaneous cell differentiation, 
characterized by down-regulation of specific stem cell 
markers involved in pluripotency and self-renewal, 
and inducing morphological and phenotypical (i.e. 
expression of GFAP) features of mature astrocytes. More 
importantly, all these functional alterations determine the 
loss of the ability to develop tumors in mice, thus causing 
the differentiation of GBM tumor-initiating cells into a 
non-tumorigenic subpopulation. This evidence suggests 
that PrPC is a major regulator of GBM stem cell activity. 
Importantly, in glioma, the number of GFAP-expressing 
cells was reported to be inversely correlated to the level 
of tumor anaplasia, likely representing the content of 
undifferentiated, stem-like cells [72]. Our data are in line 
with this observation since we show that CSCs do not 
express GFAP, and that the loss of stemness induced by 
PrPC down-regulation is correlated with the induction of 
this astrocytic marker. Furthermore, we observed that the 
down-regulation of PrPC also favors CSC differentiation 
toward endothelial-like cells. In fact, when induced 
to assembly into vessel-like structures by growing in 
selective medium PrP-KO cells showed higher efficiency 
than control cells, although also these cells were able to 
undergo tube formation.
PrPC role in the regulation of cell stemness has 
been also described in different cell models, involving 
normal neural stem cells: Prodromidou et al. observed 
that PrPC depletion reduces proliferation rate and 
secondary neurosphere formation of neuronal progenitors 
isolated from mouse subventricular zone [73]; Santos 
et al. demonstrated that neurospheres formation from fetal 
forebrain of PRNP(0/0) mice was significantly reduced when 
compared with the wild-type counterparts [28]; Mohanty 
et al. showed a significant reduction in proliferation and 
clonogenic potential in human mesenchymal stem cells 
when PrP expression was down-regulated [74]. Similarly, 
PrPC was also shown to influence the proliferation of 
human CSCs in which a population of CD44+/PrPC+ cells 
was isolated from primary colorectal tumors, showing an 
enhanced tumor-initiating and metastatic ability [37].
Our data extend this evidence to human GBM 
CSCs, reporting that the reduction of PrPC expression is 
associated with a significant reduction of proliferation 
rate and tumorigenicity. We demonstrate that these effects 
are related to the decrease of the expression of different 
transcription factors, such as Sox2 and NANOG, essential 
for maintaining self-renewal or pluripotency of both 
normal stem cells and CSCs, resulting in the activation 
of a differentiating program and loss of tumorigenicity. 
Interestingly, these factors have been linked to abnormal 
proliferation and oncogenic transformation [75] and 
NANOG is up-regulated in radio-resistant GBM stem 
cells [76]. On the other hand, Sox2 down-regulation in 
GBM CSCs causes cell growth arrest and loss of in vivo 
tumorigenicity [77], further confirming the relevance of 
the alterations induced by PrPC-KO we highlight in this 
study.
The intracellular mechanisms responsible for 
these regulation have not been yet completely defined. 
It is known that PrPC, although mainly localized on the 
membrane, modulates different transduction mechanism 
including Fyn or other c-src-like kinases [30]. Thus, 
we can hypothesize that a constitutive activation of 
components of this kinase family by PrPC might control 
the expression of stemness and self-renewal factors, as 
demonstrated for Lck in established glioma cell lines [78]. 
In fact, PrPC-dependent activation of c-src-like kinases 
(Fyn and Yes) sustains β-catenin activity, a main regulator 
of SOX2 expression [79]. Further studies are required to 
directly address this issue.
Different recent studies show that GBM CSCs play 
a central role in sustaining long-term tumor growth after 
chemotherapy [43, 80], underlying the importance of the 
identification of specific pharmacological targets in this 
GBM cell subpopulation. Other reports suggest that the 
induction of CSC differentiation could represent a new 
therapeutic strategy against GBM [81–83], and that tumors 
enriched in differentiated cells (i.e. co-expressing aldehyde 
dehydrogenase 1A1 and GFAP but not nestin or Sox2) 
correlate with better patients’ survival [84]. Interestingly, 
PrPC displays a significant plasticity in human tumors 
and thus it represents a potential therapeutic target. For 
example, PrPC overexpression is induced in breast cancer 
cells by endoplasmic reticulum stress, conferring to 
tumor cells increased resistance to cytotoxic stimuli [85]. 
All in all, the induction of GBM CSC differentiation by 
PrPC down-regulation, or its functional inhibition, could 
represent a relevant novel approach in this field.
In conclusion, our data point out that PrPC plays a 
central role in GBM cell stemness and tumorigenesis, and 




Anti-PrP antibodies: 3F4 (mouse) (Signet Lab, 
London, UK), Saf 32 (mouse) (Bertin Pharma, France); 
anti-β actin (mouse), anti-GFAP (rabbit), anti-NANOG 
(rabbit) (Abcam, Cambridge, UK); anti-Sox2 (rabbit) 
(Merck Millipore, Darmstadt, Germany).
Secondary antibodies: Alexa-Fluor 488-conjugated 
anti-rabbit IgG (Molecular Probes, Invitrogen Corp., 
Carlsbad, CA, USA) for immunofluorescence, and 
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horseradish peroxidase-linked anti-mouse or anti-rabbit 
IgG antiserum (GE Healthcare, Milano Italy) for Western 
blots.
Human GBM specimens
Tumor specimens were obtained from 
Neurosurgery Dept. IRCCS-AOU San Martino-IST 
(Genova, Italy), after Institutional Ethical Committee 
approval of the informed consent provided to patients 
and the ex vivo human sample study. Tumors were 
diagnosed as primary WHO grade IV GBM. GBM1 
(neural) occurred in a 67 year-old man, with a right 
hemisphere localization and a cortical development; 
GBM2 (neural) occurred in 48 year-old men, with a left 
hemisphere localization and a sub-cortical development; 
GBM3 (mesenchymal) occurred in 41 year-old women 
with a right fronto-temporal localization and cortical 
diffusion; GBM4 (neural) occurred in 70 year-old 
women with a right hemisphere localization and a sub-
cortical development. Patients underwent first-time 
surgery and never received chemo- or radio-therapy. 
Immunohistochemical analysis showed a MIB index 
of 40% for GBM1 and GBM4, 60% for GBM2, and 
35% for GBM3; all tumors were GFAP+ and no signs of 
meningeal invasion was detected, with the exception of 
GBM3. Upon arrival in the laboratory, tumor specimens 
were immediately processed to isolate single cells 
by mechanical dissociation and cell suspension was 
filtered through a 40 μm strainer (BD Biosciences, 
Buccinasco, MI, Italy) to remove aggregates, and 
cultured as previously described [46].
Human GBM CSC cultures
Cells were grown in stem cell-permissive medium 
[DMEM-F12/Neurobasal (1:1), supplemented with 
1% B27 (Life Technologies, California, USA), 2 mM 
L-glutamine (Lonza Srl, Milano, Italy), 100 u/ml 
penicillin/streptomycin (Lonza), 10 ng/ml bFGF and 
20 ng/ml EGF (PeproTech, London,UK)] [47]. Cells 
were grown as monolayer on Matrigel (BD Biosciences 
Milano, Italy), as reported [46]. In these conditions, cells 
retain CSC features as routinely assessed by stem cell 
marker expression and in vivo tumorigenicity [46]. This 
culture condition was used to obtain easier evaluation 
of cell biology and biochemical experiments, rather 
than using non-adherent spheroids. To induce cell 
differentiation, CSC cultures were shifted to growth 
factor-deprived medium containing 10% fetal bovine 
serum (FBS, Lonza) for at least 2 wk. GBM CSC 
tumorigenicity was assayed by intracranial inoculation 
of 104 cells/mouse, in 6–8-wk-old NOD/SCID mice 
(Charles River, Calco, Italy), in compliance with 
guidelines approved by Ethical Committee for animal 
use in cancer research at IRCCS-AOU San Martino-IST 
(Genova, Italy).
Stable silencing of PrP expression in GBM CSC 
cultures
GBM CSCs were transfected with PrP shRNA 
Plasmid (h) (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA); this is a pool of 3 target-specific lentiviral vector 
plasmids each encoding 19-25 nt (plus hairpin) shRNAs, 
designed to knock-down gene expression.
Briefly, 24 hours before the transfection, cells 
were seeded at 50-70% confluence in a six well tissue 
culture plate in stem cell permissive medium. Ten ml of 
shRNA plasmid DNA (1 μg), diluted in 90 ml of shRNA 
Plasmid Transfection Medium were mixed with a solution 
containing 4 μl shRNA Plasmid Transfection Reagent and 
96 μl of shRNA Plasmid Transfection Medium (Santa Cruz 
Biotechnology) for 45 min according to the manufacturer’s 
instructions. Cells were washed twice with 2 ml of shRNA 
Transfection Medium, and for each transfection, 0.8 ml 
shRNA Plasmid Transfection Medium and 200 μl shRNA 
Plasmid DNA/shRNA Plasmid Transfection Reagent was 
added. After 8 hrs at 37°C in a CO2 incubator, 1 ml of 
DMEM-F12/Neurobasal medium, containing 2 times the 
normal serum and antibiotics concentrations, was added. 
After additional 20 hrs, infected cells were moved in stem 
cell permissive medium and selected by adding puromycin 
(5 μg/ml). The same procedure was performed with 
control plasmid encoding a scrambled shRNA sequence 
that will not lead to the specific degradation of any known 
cellular mRNA.
Using this protocol we generate GBM-PrP-KO and 
GBM-Scr (control) cells.
Western blot
Cells were lysed in a buffer containing 20 mM Tris-
HCl pH 7.4, 140 mM NaCl, 2 mM EDTA, 2 mM EGTA, 
10% glycerol, 1% NP-40, 1 mM dithiothreitol, 1 mM 
sodium orthovanadate, 1 mM phenylmethylsulphonyl 
fluoride, and the “Complete” protease inhibitor cocktail 
(Roche, Monza, Italy), as reported [86]. Twenty-
five micrograms of proteins from each sample were 
size-fractionated by 12% SDS-PAGE, transferred 
to a poly-vinylidene difluoride membrane (Bio-Rad 
Laboratories, Hercules, CA, USA), and probed with 
the primary antibodies. The secondary antibody was a 
horseradish peroxidase-linked anti-rabbit IgG or anti-
mouse IgG antiserum (GE Healthcare, Milano, Italy). 
Antibody-reactive bands have been detected by ECL 
(GE Healthcare) using ChemiDoc™ MP Systems (Bio-
Rad, Segrate, Italy).
Immunocytofluorescence
GBM cells were fixed with 4% paraformaldehyde, 
permeabilized with PBS/0.1% Triton X-100, blocked with 
normal goat serum and immunostained with anti-GFAP 
antibody (rabbit polyclonal, 1:1,0000, Abcam, Cambridge, 
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UK). Fluorochrome-conjugated antibody (goat anti-rabbit 
Alexa Fluor-488, Molecular Probes, Oregon, USA) was 
added, nuclei were counterstained with DAPI (Sigma-
Aldrich, Milano, Italy), and cell morphology evidenced 
by Dil (Molecular Probes) a lipophilic red-fluorescent dye 
that stains plasma-membranes and cytoplasmic vesicles 
[6]. Slides were photographed with DM2500 microscope 
(Leica, Milano, Italy) equipped with DFC350FX digital 
camera (Leica).
Cell proliferation assay
Mitochondrial activity, an index of cell 
viability, was evaluated by measuring the reduction of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT, Sigma-Aldrich). After treatments, cells 
were incubated with MTT (2 mg/ml) for 1h, formazan 
crystals dissolved in DMSO and absorbance measured 
at 570 nm [87].
Cell Counting
CSCs from different GBMs, grown in standard 
conditions for 3 days, were counted with an automated 
cell counter every 24 hours. Cells were harvested and the 
cell suspension diluted 1:10 in sterile PBS and mixed with 
an equal volume of 0.4 % Trypan Blue solution to evaluate 
the number of live/dead cells using TC20 Cell Counter 
(Bio-Rad Laboratories, Inc., Hercules, CA) [88].
BrdU incorporation ELISA
DNA synthesis was evaluated by assessing 5-bromo-
2’-deoxyuridine (BrdU) incorporation during DNA synthesis 
(Cell proliferation ELISA, Roche), as reported [71].
Clonogenicity assay
To verify the effect of PrPC down-regulation on 
GBM CSC stemness, an in vitro assay based on the 
ability of a single cell to grow into a colony was used 
[89]. GBM-Scr and GBM-PrP-KO cells were seeded with 
scalar dilution in 96-well microplates without Matrigel to 
reach a concentration lower than 1 cell/well. After 24 h, 
wells were visually inspected under a light microscope, 
and wells containing no live cells or more than 1 cell were 
excluded. Cells were maintained in complete medium for 
a week to allow the clonal growth. After 7 days clones 
were visually inspected by light microscopy and counted 
by three independent operators.
Sphere-formation assay
We used the sphere limiting dilution analysis 
to evaluate sphere formation in GBM-Scr and GBM-
PrP-KO. GBM cells were cultured as primary spheres. 
Morphology of the spheres developed in the wells was 
evaluated using a digital camera Leica ICC50 HD (Leica) 
mounted on a transmitted light microscope DM IL (Leica) 
to image each individual well [48]. Subsequently, spheres 
were dissociated with Accutase™ for 5 min at 37 °C and 
mechanically disaggregated until a single cell suspension 
was achieved. Cells were then plated at densities ranging 
from 100 to 0.01 cells across two 96 well plates in 200μl 
of complete medium with 16 replicates for each dilution 
and then evaluated for secondary sphere formation after 
15 days in culture. We scored each well for the absence 
or presence of sphere growth to determine the fraction of 
negative wells. The plot shows natural log transformation 
for the fraction of non-responding wells (y-axis) versus 
plating density (x-axis). The probability of forming a 
sphere is determined by the x intercept (cell density) when 
y=−1 [53].
Endothelial tube formation assays
μ–Slide Angiogenesis (Ibidi, Munich, Germany) 
were coated with Matrigel (BD Biosciences) and 
allowed to polymerize at 37°C for 30 min. 104 cells were 
subsequently seeded and incubated at 37°C for 24h, in 
Endogro medium to induce endothelial transdifferentiation 
(Merck Millipore, Darmstadt, Germany). Tube-like 
structures were photographed using a phase contrast 
microscope. To quantify the results, we counted the mean 
loop perimeter and the number of branch points, in which 
at least 3 tubes joined, using the ImageJ software.
RNA extraction and quantitative real-time PCR 
(qRT-PCR)
Total RNA was extracted using the High Pure RNA 
Isolation Kit (Roche), according to the manufacturer’s 
instruction, and reverse transcribed into cDNA using the 
iScript cDNA Synthesis Kit (Bio-Rad) [90].
Single stranded cDNA products were analyzed 
by real-time PCR using the SsoFastTM EvaGreen mix 
(Bio-Rad) on a CFX96 Touch real-time PCR (Bio-Rad). 
Cycling conditions were set at 94° C for 30 s, 60° C for 30 
s and 72° C for 30 s, for 37 cycles.
Primer sequences were designed on the mature 
transcripts:
NANOG: forward: 5′-GTCCCAAAGGCAAACA 
ACCC-3′; reverse: 5′-TTGACCGGGACCTTGTCTTC-3′;
Sox2: forward: 5′-CAGGAGTTGTCAAGGCAGA 
GA-3′; reverse: 5′-GTCCTAGTCTTAAAGAGGCAG 
CA-3′;
PrP: forward: 5′-AGTGGAACAAGCCGAGTAA 
GC 3′; reverse:
5′-GTCACTGCCGAAATGTATGATG-3′
GAPDH: forward: 5′-ACCCACTCCTCCACCTT 
TGA-3′; reverse: 5′-CTGTTGCTGTAGCCAAATTCGT-3
28S: forward: 5′-CCCAGTGCTCTGAATGTC 
AA-3′; reverse: 5′-AGTGGGAATCTCGTTCATCC-3′.
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Levels of target genes in each sample were 
normalized on the basis of GAPDH and 28S amplification 
and reported as relative values. All qRT-PCR runs included 
negative controls without mRNA templates and cDNA 
transcription to check reagents for contaminations.
In vivo tumorigenicity experiments
For in vivo experiments all the institutional and 
national guidelines for the care and use of laboratory 
animals were followed and the experimental plan approved 
by the committee for ethical animal use at IRCCS AOU S. 
Martino-IST, Genova, Italy. The tumor initiating potential 
of Scr- or PrP-silenced GBM cells was evaluated by 
orthotopic transplantation into 8 weeks-old NOD/SCID 
mice, as already described [46]. We injected 10,000 
cells, since we previously showed that it allowed a tumor 
take rate of 100% of the animals, while this value was 
decreased to 40% with 1,000 cells and less than 20% with 
100 cells [49]. Briefly, 10,000 cells were stereotactically 
injected into the striatum of ketamine-anesthetized mice, 
at 3 mm of depth, and tumors allowed to develop. Animals 
(n=4 in the different experimental groups) were monitored 
daily for neurological signs and all were sacrificed 
when first signs of morbidity was detected in one of the 
experimental groups. Collected brains were cryopreserved 
and 10-mm cryostat (Leica Microsystems) sections were 
cut. Sections bearing tumors were identified by H&E.
Statistical analysis
Unless specified, all experiments were replicated 
three times. Data are reported as means ± SEM. Statistical 
analysis (ANOVA) was performed using IBM-SPSS 
9.0 software (IBM Italia, Milano, Italy). p ≤ 0.05 was 
considered statistically significant.
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